Merck, Gilead, and Others Turn External Sourcing Into a Repeatable Pipeline Reset

Large drugmakers are building a repeatable deal engine to refill pipelines with de-risked assets and faster commercial paths.

Updated

What is this trend?

Big biopharma is turning acquisitions and partnerships into a repeatable system for replacing pipeline gaps with de-risked, clinically credible assets.

  • Buyers want late-stage or validated assets, not long-shot discovery bets.
  • Clean rights, CMC readiness, and integration speed are now premium features.
  • Regional flexibility and co-marketing options can make deals more attractive.
  • External sourcing is becoming a standing pipeline function, not a one-off fix.

What’s the latest?

Merck’s $6.7 billion Terns buy, Gilead’s $7.8 billion Arcellx deal, Roche/Bayer’s continued targeted partnering, Celltrion’s up-to-$580.5 million Kaigene agreement, and Ambrose’s €161 million-plus-roy

AI Moves Into Trial Ops, Big Pharma Resets Sourcing, and Biotech Transfer Rules Tighten

How it developed

  1. Platform Access Over Asset Buys, and Diagnostics AI as Oncology’s New Moat
    • Platform Access and Regional Rights Are Replacing One-Off Asset Buys

  2. Integrated discovery stacks, domestic IP control, and de-risked assets reshape biotech dealmaking
    • Pipeline Replacement Deal Demand

  3. Platform-Buying Spree, Onshoring Control, and Diagnostics Gatekeeping Tighten Biopharma Value Chains
    • Pipeline Replacement Deal Demand

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Biotechnology

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.